Modified risk stratification based on cervical lymph node metastases following lobectomy for papillary thyroid carcinoma

甲状腺癌 医学 危险分层 淋巴结 内科学 肿瘤科 内分泌学 甲状腺
作者
Eyun Song,Jong Hwa Ahn,Dong Eun Song,Won Woong Kim,Min Ji Jeon,Tae‐Yon Sung,Tae Yong Kim,Ki‐Wook Chung,Won Bae Kim,Young Kee Shong,Suck Joon Hong,Yu‐Mi Lee,Won Gu Kim
出处
期刊:Clinical Endocrinology [Wiley]
卷期号:92 (4): 358-365 被引量:5
标识
DOI:10.1111/cen.14115
摘要

Evidence for American Thyroid Association (ATA) risk stratification stems largely from studies involving patients undergoing total thyroidectomy. We aimed to assess the risk of recurrence according to the present ATA risk stratification system in patients who underwent lobectomy.Retrospective cohort study.Patients who underwent thyroid lobectomy for 1-4 cm-sized papillary thyroid carcinoma (n = 571).Disease-free survival (DFS) was compared according to the ATA risk stratification, and specific lymph node (LN) characteristics were evaluated to modify the ATA criteria with a higher predictability for recurrence.Based on the ATA risk stratification, 439 patients (61.1%) were classified into intermediate- or high-risk group, and consideration for completion thyroidectomy is suggested by ATA guidelines for these patients. However, no significant differences were found in DFS among the low-, intermediate- and high-risk groups (P = .9). In contrast, when patients were stratified according solely to the LN criteria from the ATA risk stratification, only 127 patients (22.2%) had intermediate risk (intermediate-N1a) and exhibited significantly poorer DFS than those with N0 disease (P = .035). Modifying the intermediate-N1a criteria by adding the extranodal extension (ENE) status and omitting the clinical nodal disease enabled the subclassification of 19 patients (3%) with a high risk for recurrence.The present study suggests that risk stratification based solely on LN metastases is more reasonable for predicting structural persistence/recurrence following lobectomy than that based on the overall ATA criteria. Considering the ENE status can assist in selecting patients with a high risk of recurrence to minimize further treatments.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
1秒前
1秒前
酷酷的山雁完成签到,获得积分10
2秒前
完美世界应助xueshu采纳,获得10
2秒前
乐乐应助AXEIFORM采纳,获得10
2秒前
落落完成签到,获得积分10
3秒前
量子星尘发布了新的文献求助10
5秒前
5秒前
喵喵机关注了科研通微信公众号
6秒前
zhou发布了新的文献求助10
6秒前
bobo1129完成签到,获得积分10
7秒前
whoami完成签到,获得积分10
8秒前
xvzhenyuan发布了新的文献求助10
9秒前
jmn完成签到,获得积分10
9秒前
超级映安发布了新的文献求助10
9秒前
li完成签到,获得积分10
11秒前
老福贵儿应助李土豆采纳,获得10
12秒前
12秒前
13秒前
謃河鷺起完成签到,获得积分10
13秒前
sjk完成签到,获得积分10
13秒前
领导范儿应助雨碎寒江采纳,获得10
13秒前
科研通AI6应助科研通管家采纳,获得10
13秒前
隐形曼青应助科研通管家采纳,获得10
13秒前
zhonglv7应助科研通管家采纳,获得10
13秒前
ilihe应助科研通管家采纳,获得30
14秒前
SciGPT应助科研通管家采纳,获得10
14秒前
彭于晏应助科研通管家采纳,获得10
14秒前
liao应助科研通管家采纳,获得10
14秒前
传奇3应助科研通管家采纳,获得10
14秒前
852应助科研通管家采纳,获得10
14秒前
re应助科研通管家采纳,获得10
14秒前
完美世界应助科研通管家采纳,获得10
14秒前
科研通AI6应助科研通管家采纳,获得10
14秒前
浮游应助科研通管家采纳,获得10
14秒前
852应助山槐采纳,获得10
14秒前
liao应助科研通管家采纳,获得10
14秒前
香蕉觅云应助科研通管家采纳,获得10
14秒前
科研通AI6应助科研通管家采纳,获得10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2025-2031全球及中国金刚石触媒粉行业研究及十五五规划分析报告 9000
Encyclopedia of the Human Brain Second Edition 8000
Translanguaging in Action in English-Medium Classrooms: A Resource Book for Teachers 700
Real World Research, 5th Edition 680
Qualitative Data Analysis with NVivo By Jenine Beekhuyzen, Pat Bazeley · 2024 660
Chemistry and Biochemistry: Research Progress Vol. 7 600
热门求助领域 (近24小时)
化学 材料科学 生物 医学 工程类 计算机科学 有机化学 物理 生物化学 纳米技术 复合材料 内科学 化学工程 人工智能 催化作用 遗传学 数学 基因 量子力学 物理化学
热门帖子
关注 科研通微信公众号,转发送积分 5684019
求助须知:如何正确求助?哪些是违规求助? 5034811
关于积分的说明 15183309
捐赠科研通 4843392
什么是DOI,文献DOI怎么找? 2596672
邀请新用户注册赠送积分活动 1549384
关于科研通互助平台的介绍 1507854